Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00248170 · OUTCOME

Percentage of Participants Who Experienced Cardiovascular Events

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer · Source last updated 2016-04-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
84 months

What was measured

The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.

Analysis population: Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.

Groups in this outcome

Letrozole

2.5 mg by mouth (p.o.) once daily

Anastrozole

1 mg p.o. once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Letrozole2049
Anastrozole2062

Reported measurements

Ischemic heart disease
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole2.4Not reportedNot reportedNot reportedNot reported
Anastrozole1.5Not reportedNot reportedNot reportedNot reported
Cardiac failures
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole1.5Not reportedNot reportedNot reportedNot reported
Anastrozole0.7Not reportedNot reportedNot reportedNot reported
Cerebrovascular accidents
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole1.6Not reportedNot reportedNot reportedNot reported
Anastrozole1.5Not reportedNot reportedNot reportedNot reported
Thromboembolic events
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole1.2Not reportedNot reportedNot reportedNot reported
Anastrozole1.2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2.4
      2. group Id
        OG001
        value
        1.5
    title
    Ischemic heart disease
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1.5
      2. group Id
        OG001
        value
        0.7
    title
    Cardiac failures
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1.6
      2. group Id
        OG001
        value
        1.5
    title
    Cerebrovascular accidents
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1.2
      2. group Id
        OG001
        value
        1.2
    title
    Thromboembolic events
denoms
  1. counts
    1. group Id
      OG000
      value
      2049
    2. group Id
      OG001
      value
      2062
    units
    Participants
description
The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.
groups
  1. description
    2.5 mg by mouth (p.o.) once daily
    id
    OG000
    title
    Letrozole
  2. description
    1 mg p.o. once daily
    id
    OG001
    title
    Anastrozole
param Type
NUMBER
population Description
Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.
reporting Status
POSTED
time Frame
84 months
title
Percentage of Participants Who Experienced Cardiovascular Events
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice